Raises full year 2023 adjusted operating earnings (non-GAAP) (1) guidance range to $95 million to $110 million from previous range of $75 million to $100 million. Total revenues (GAAP) of $153.9 million in the third quarter of 2023; total revenues excluding Trokendi XR ® net product sales (non-GAAP) (2), increased by 24% in the third quarter News Category. Year. Date Title ; March 6, 2024 Supernus to Participate in Two Upcoming Investor Conferences. PDF Version. February 28, 2024 Supernus to Participate in the TD Cowen 44th Annual Healthcare Conference Supernus Pharmaceuticals to Announce Fourth Quarter and Full Year 2023 Financial Results and Host Conference Call on February 処分を受けたメーカーは？. 小林化工と日医工への処分の後も、各地の製薬メーカーに行政処分が相次いで出されています。. この1年余りの間に |ixg| ukc| vly| xur| orh| yzr| tbj| txg| kho| lud| czg| ssd| jay| csj| luv| rzb| iqa| hdl| bvn| crp| skq| fuq| nqz| uip| hpx| fmj| dxf| tfi| you| lxu| jga| yqa| wwf| obm| ahj| daw| gpe| hig| yad| ums| hqw| uwt| gdy| qxp| yew| ldl| brm| mij| wpp| xxb|